secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001048477-23-000041
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin Q3 2023: revenue $581M (+15% YoY), VOXZOGO $123M (+155%), cuts ROCTAVIAN guidance
--------------------------------------------------------------------------------

- Q3 total revenue $581.3M (+15% YoY), GAAP net income $40.4M vs loss $6.7M, GAAP diluted EPS $0.21 vs ($0.04).
- VOXZOGO revenue $123.1M (+155% YoY); full-year guidance raised to $435-455M from $400-440M.
- ROCTAVIAN revenue $0.8M; full-year guidance slashed to <$10M from $50-150M due to pricing delays.
- Full-year 2023 total revenue guidance narrowed to $2.39-2.47B; Non-GAAP diluted EPS guided $1.90-2.05.
- Management expects 2024 revenue to approach $3B; VOXZOGO age expansions in US and EU; hypochondroplasia trial to start.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847723000041/0001048477-23-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847723000041/bmrn-20231101.htm
  HTML page:      https://secwatch.observer/filing/0001048477-23-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer